emedastine (emadine) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfavorable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.   NCATS

Chemistry

  • SMILES: CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21
  • InChIKey: KBUZBQVCBVDWKX-UHFFFAOYSA-N
  • Mol. Mass: 302.42
  • ALogP: 2.21
  • ChEMBL Molecules:
    emedastine  
    emedastine difumarate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Alternative names

1-(2-ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1h-benzoimidazole | 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole | 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate | 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole | al-3432a | daren | emadine | emedastina | emedastine | emedastine difumarate | emedastine difumarate ophthalmic solution | emedastine fumarate | emedastinum | kb 2413 | kb-2413 | kg 2413 | kg-2413

Organizations (3)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Conjunctivitis, Allergic (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Rhinitis, Allergic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue